| |
CRC-related mortality
|
Overall mortality
|
|---|
| |
No. of deaths (%)
|
HR
b
|
95% CI
|
P
for Heter.
|
No. of deaths (%)
|
HR
b
|
95% CI
|
P
for Heter.
|
|---|
|
Age- and country-adjusteda
|
872 (26.5)
|
0.92
|
(0.86–0.98)
| |
1,113 (33.8)
|
0.92
|
(0.87–0.97)
| |
|
Multivariate adjustedb
|
872 (26.5)
|
0.90
|
(0.83–0.97)
| |
1,113 (33.8)
|
0.93
|
(0.87–0.99)
| |
|
Sensitivity analyses
c
| | | | | | | | |
|
Excluding deaths within 6 mo of diagnosis
|
717 (24.4)
|
0.89
|
(0.82–0.97)
| |
858 (29.2)
|
0.92
|
(0.85–0.99)
| |
|
Participants with complete CRC stage data
|
618 (25.6)
|
0.88
|
(0.80–0.96)
| |
783 (32.4)
|
0.91
|
(0.84–0.98)
| |
|
Effect modification analyses
c
| | | | | | | | |
|
By sex
| | | |
0.983
| | | |
0.597
|
|
Men
|
408 (27.3)
|
0.89
|
(0.79–1.00)
| |
531 (35.5)
|
0.90
|
(0.81–0.99)
| |
|
Women
|
464 (25.8)
|
0.91
|
(0.82–1.01)
| |
582 (32.4)
|
0.96
|
(0.88–1.06)
| |
|
By mean age at diagnosis
| | | | | | | | |
|
<64.6 years
|
425 (26.4)
|
0.89
|
(0.80–0.99)
|
0.985
|
515 (32.0)
|
0.91
|
(0.82–0.99)
|
0.553
|
|
≥64.6 years
|
447 (26.5)
|
0.92
|
(0.83–1.03)
| |
598 (35.5)
|
0.97
|
(0.89–1.07)
| |
|
By year of diagnosis
| | | | | | | | |
|
1992–2001
|
548 (33.5)
|
0.88
|
(0.80–0.96)
|
0.889
|
691 (42.2)
|
0.90
|
(0.82–0.98)
|
0.415
|
|
2002–2008
|
324 (19.6)
|
0.93
|
(0.82–1.06)
| |
422 (25.5)
|
0.96
|
(0.86–1.08)
| |
|
By median ‘lag time’
d
| | | | | | | | |
|
<6.5 years
|
550 (33.3)
|
0.85
|
(0.77–0.94)
|
0.251
|
687 (41.6)
|
0.88
|
(0.81–0.96)
|
0.094
|
|
≥6.5 years
|
332 (20.2)
|
0.96
|
(0.84–1.08)
| |
426 (26.0)
|
0.99
|
(0.88–1.10)
| |
|
By tumor stage
| | | | | | | | |
|
I
|
51 (8.5)
|
0.86
|
(0.62–1.20)
|
0.279
|
76 (12.6)
|
0.80
|
(0.61–1.04)
|
0.067
|
|
II
|
78 (12.8)
|
0.87
|
(0.68–1.12)
| |
108 (17.7)
|
0.85
|
(0.69–1.06)
| |
|
III
|
294 (34.1)
|
0.87
|
(0.75–1.00)
| |
369 (42.8)
|
0.94
|
(0.83–1.07)
| |
|
IV
|
195 (57.9)
|
0.86
|
(0.72–1.04)
| |
230 (68.2)
|
0.85
|
(0.72–1.01)
| |
|
By tumor site
| | | |
0.263
| | | |
0.137
|
|
Colon
|
537 (25.9)
|
0.95
|
(0.86–1.05)
| |
693 (33.5)
|
0.99
|
(0.90–1.07)
| |
|
Rectum
|
355 (29.1)
|
0.85
|
(0.75–0.97)
| |
420 (34.4)
|
0.86
|
(0.77–0.96)
| |
|
By colon sub-site
| | | |
0.490
| | | |
0.168
|
|
Proximal
|
288 (30.3)
|
1.07
|
(0.92–1.25)
| |
310 (32.6)
|
1.09
|
(0.95–1.24)
| |
|
Distal
|
246 (26.1)
|
0.81
|
(0.70–0.94)
| |
301 (31.9)
|
0.84
|
(0.73–0.96)
| |
|
By smoking status
| | | |
0.892
| | | |
0.773
|
|
Never smoker
|
365 (26.7)
|
0.86
|
(0.77–0.97)
| |
448 (32.7)
|
0.94
|
(0.84–1.05)
| |
|
Former smoker
|
286 (25.6)
|
0.91
|
(0.79–1.05)
| |
372 (33.3)
|
0.89
|
(0.79–1.01)
| |
|
Current smoker
|
214 (27.6)
|
1.00
|
(0.86–1.16)
| |
282 (36.4)
|
0.96
|
(0.84–1.10)
| |
- aCox regression model, with age at CRC diagnosis as entry time and age at death or censoring as exit time, stratified by country; bMultivariable adjusted models were further adjusted for year of CRC diagnosis, tumor stage, tumor grade, tumor site, sex, educational level, and smoking status; cSensitivity and stratified analyses were based on multivariable adjusted model; d‘Lag-time’ means years between recruitment and CRC diagnosis.
